Compare Cassava Sciences Inc (FLNA) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Koninklijke Philips NV — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Koninklijke Philips NV trades at $27.21 (market cap $26.29B). The key difference: Koninklijke Philips NV is far larger — about 494.7× Cassava Sciences Inc's market cap, and Koninklijke Philips NV pays a 3.75% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PHG | |
|---|---|---|
Market Cap | $53.14M | $26.29B |
Sector | Health | Health |
52-Week High | $4.64 | $32.91 |
52-Week Low | $1.09 | $24.38 |
Enterprise Value | -$33.43M | $32.56B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
PHG trades at $27.16, up 4.22% today. The stock shows mixed signals with a bearish technical outlook but improving fundamentals, including a return to profitability in 2025 with net income of $895 million. Recent news highlights AI integration in healthcare products and new FDA clearances, supporting growth initiatives. Analyst consensus is divided with 41% buy ratings amid neutral sentiment.
The outlook is cautiously optimistic given earnings recovery and strategic partnerships, but risks include high debt levels and competitive pressures. The stock presents a value opportunity if operational improvements continue, though technical weakness suggests near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
